Global Spinal Muscular Atrophy and Muscular Dystrophy Gene Therapies Market Strategic Research Report

The global spinal muscular atrophy (SMA) and muscular dystrophy gene therapies market represents one of the most commercially significant frontiers in rare neurological disease treatment. Valued at approximately USD 6.8 billion in 2024, the market has been transformed over the past decade by the clinical validation of gene replacement and gene editing approaches that address the underlying genetic defects causing these devastating neuromuscular conditions. SMA—driven predominantly by loss-of-function mutations in the SMN1 gene—and Duchenne muscular dystrophy (DMD), caused by dystrophin gene mutations, together affect hundreds of thousands of patients globally, creating a concentrated but high-value addressable market. The commercial success of pioneering therapies such as onasemnogene abeparvovec (Zolgensma) and the accelerating regulatory acceptance of micro-dystrophin gene therapies have anchored investor confidence and sustained near-record R&D expenditure across the sector.

Three specific forces are propelling market expansion at a projected CAGR of 14.2% through 2032. First, newborn screening program expansion across the United States, European Union, and Australia is identifying SMA patients at pre-symptomatic stages, dramatically broadening the eligible treatment population and enabling earlier, higher-cost therapeutic intervention. Second, the maturation of adeno-associated virus (AAV) manufacturing technology—particularly improvements in capsid engineering and scalable production yields—is reducing cost-of-goods for gene therapy manufacturers, supporting more accessible pricing and improving operating margins. Third, regulatory pathway clarity, including the FDA's accelerated approval framework and EMA's adaptive pathways for rare diseases, has shortened average time-to-market for next-generation products, attracting mid-tier biotechs and large pharmaceutical acquirers alike. The principal restraint remains therapy durability uncertainty: long-term follow-up data on single-dose gene therapies are still accumulating, creating payer hesitancy around formulary coverage and reimbursement negotiations, particularly in cost-sensitive European markets.

This report delivers a comprehensive, data-anchored assessment of the SMA and muscular dystrophy gene therapies market from 2019 through 2032, covering product type segmentation, application segmentation by disease indication, regional and country-level revenue forecasts, competitive profiling of ten key companies, and structured analyses of competitive intensity, regulatory environment, and emerging technological trends. It is intended for corporate strategy teams evaluating pipeline investments, investment analysts conducting due diligence on gene therapy assets, M&A advisors assessing acquisition targets, and procurement managers at hospital systems and specialty pharmacy networks navigating ultra-high-cost therapy contracting.